OncoMatch/Clinical Trials/NCT05631249
Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
Is NCT05631249 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Sotorasib 120Mg Tab for kras p.g12c.
Treatment: Sotorasib 120Mg Tab — This study aims to provide a comprehensive understanding of sotorasib's mechanisms of action and resistance in NSCLC patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS G12C mutation
KRAS p.G12C mutation confirmed through molecular testing (results of both tissue and liquid biopsy are accepted)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: kras inhibitor
Lab requirements
Blood counts
adequate bone marrow reserve and organ function, based on local laboratory data within 14 days prior to registration
Kidney function
adequate organ function, based on local laboratory data within 14 days prior to registration
Liver function
adequate organ function, based on local laboratory data within 14 days prior to registration
Have adequate bone marrow reserve and organ function, based on local laboratory data within 14 days prior to registration
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05631249 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior kras inhibitor disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS G12C mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify